We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Guidance for people with symptoms of a respiratory infection including COVID-19, or a positive test result for COVID-19.
How to use a before-and-after study to evaluate your digital health product.
Information on the reporting, investigation and management of acute flaccid paralysis (AFP) and acute flaccid myelitis (AFM).
Check the tariff classification for flavour pods.
Using an ecological momentary assessment to evaluate your digital health product.
Information to support your recovery after COVID-19.
Business rates information letters are issued by the Department for Levelling Up, Housing and Communities at regular intervals throughout the year.
The agreement for a first-of-a-kind test rig will provide critical data for the design and development of Spherical Tokamak for Energy Production (STEP).
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
How to use a crossover randomised controlled trial to evaluate your digital health product.
Information for clinicians and patients.
Further measures to be introduced to ensure patients who are prescribed montelukast for the treatment of asthma are informed of the risk of neuropsychiatric reactions
How you might know if your company is in distress.
Information to assist with differentiating Lyme disease from other causes of rash, neurological or non-specific symptoms.
How to create a model of how your digital health product works and choose measures for your evaluation.
Weekly national influenza and COVID-19 report, COVID-19 activity, seasonal flu and other seasonal respiratory illnesses.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Read about talking therapies and counselling for mental health problems.
How to design, inspect, monitor and maintain impounding reservoir spillways so they are safe.
This toolkit is for Innovation Passport holders following the Innovative Licensing and Access Pathway (ILAP) and provides activities to support the design and development of medicines.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.